How the (TENK) price action is used to our Advantage

Stock Information for Citius Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Oncology Inc.

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.